Commercial collaborations and activities are central to our work at NIHR Cambridge Biomedical Research Centre and we are pleased to be working in partnership with a range of private and public sector and charitable partners.
Their investment in, and support for, our research is enabling us to develop our understanding of cancer in order to develop new treatments. Cambridge BRC provided around £1.15m support to the Cardiovascular theme between 2009-2010, and this helped to lever over £13.66m further investment from the following organisations:
- Medical Research Council www.mrc.ac.uk
- British Heart Foundation www.bhf.org.uk
- Clinical Pharmacology Unit www-clinpharm.medschl.cam.ac.uk
- Bristol-Myers Squibb Pharmaceutical Research Institute www.bms.com
- Schering-Plough Research Institute www.merck.com
- GlaxoSmithKline www.gsk.co.uk
- National Blood Service www.blood.co.uk
- European Commission www.ec.europa.eu
- Funxional Therapeutics Ltd. www.funxionaltherapeutics.com
- NHS Blood and Transplant www.nhsbt.nhs.uk
- Merck Sharp and Dohme Ltd. www.msd-uk.com
- Novartis www.novartis.co.uk
- University of Cambridge www.cam.ac.uk
Rightnav:
Highlights
Vulnerable Plaque Imaging
The cardiovascular PET programme examines non-invasive measurement of inflammation, hypoxia and other markers of high-risk atherosclerotic plaque disease. The BRC has funded a trainee vascular surgeon who is supervising 2 ongoing translational research studies. One prospective study is investigating the determinants of aortic aneurysm expansion over a 3-year period, hypothesising that inflammation, hypoxia or neovascularisation detected by PET/CT or MRI at baseline is predictive of future aneurysm expansion.
Read more...
